Elucidating oncogenic pathways in prostate cancer is an arduous task. In this issue of Cancer Cell, Yu and colleagues show that repression of Adrenergic Receptor Beta-2 gene expression by Enhancer of Zeste 2 results in acquisition of transforming activities. It is interesting that these activities point to a role for GTPases as important regulators of transformation in prostate cancer cells. They further implicate epithelial-mesenchymal transition as a biologic end point in this process. Overall, on the basis of their findings, the authors nominate a novel oncogenic pathway for prostate cancer that deserves critical thought and attention
The original publication is available at www.springerlink.comAlthough prostate cancer is heterogeneo...
Restricted until 07 May. 2011.Prostate cancer is one of the most common forms of cancer in America a...
Prostate cancer is a heterogeneous disease arising from the epithelial cells of the prostate gland. ...
Elucidating oncogenic pathways in prostate cancer is an arduous task. In this issue of Cancer Cell, ...
This is an open-access article distributed under the terms of the Creative Commons Attribution Licen...
Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression. The het...
Prostate cancer is the most highly diagnosed, non-cutaneous cancer and second leading cause of cance...
The present work focused on the potential involvement of selective adaptations of the androgen recep...
PTEN is one of the most commonly deleted tumor suppressor genes in human prostate cancer. Our group ...
Once prostate cancer becomes castration resistant, cancer cells may rapidly gain the ability to inva...
Prostate cancer (PCa) is initially driven by excessive androgen receptor (AR) signaling with androge...
As the most frequently diagnosed cancer in North American men, prostate cancer can progress to the a...
Differentiation status influences the prognosis for localized prostate cancer. In this issue of Canc...
Prostate cancer is the most commonly diagnosed male malignancy. Despite compelling epidemiology, the...
Objective: To interrogate enriched prostate cancer cells and autologous non-malignant prostate epith...
The original publication is available at www.springerlink.comAlthough prostate cancer is heterogeneo...
Restricted until 07 May. 2011.Prostate cancer is one of the most common forms of cancer in America a...
Prostate cancer is a heterogeneous disease arising from the epithelial cells of the prostate gland. ...
Elucidating oncogenic pathways in prostate cancer is an arduous task. In this issue of Cancer Cell, ...
This is an open-access article distributed under the terms of the Creative Commons Attribution Licen...
Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression. The het...
Prostate cancer is the most highly diagnosed, non-cutaneous cancer and second leading cause of cance...
The present work focused on the potential involvement of selective adaptations of the androgen recep...
PTEN is one of the most commonly deleted tumor suppressor genes in human prostate cancer. Our group ...
Once prostate cancer becomes castration resistant, cancer cells may rapidly gain the ability to inva...
Prostate cancer (PCa) is initially driven by excessive androgen receptor (AR) signaling with androge...
As the most frequently diagnosed cancer in North American men, prostate cancer can progress to the a...
Differentiation status influences the prognosis for localized prostate cancer. In this issue of Canc...
Prostate cancer is the most commonly diagnosed male malignancy. Despite compelling epidemiology, the...
Objective: To interrogate enriched prostate cancer cells and autologous non-malignant prostate epith...
The original publication is available at www.springerlink.comAlthough prostate cancer is heterogeneo...
Restricted until 07 May. 2011.Prostate cancer is one of the most common forms of cancer in America a...
Prostate cancer is a heterogeneous disease arising from the epithelial cells of the prostate gland. ...